Healthcare decision-making is undergoing a quiet but profound shift. Clinical trials alone no longer tell the full story of how a drug or device performs — regulators, payers, and providers increasingly want to know what happens when a treatment meets real patients, in real settings, over real time. That demand is fueling rapid growth in the real world evidence solutions market:

• Market size, 2025: USD 3.0 billion
• Market estimate, 2026: USD 3.3 billion
• Market forecast, 2033: USD 6.0 billion
• Growth rate: CAGR of 9.1% from 2026 to 2033
• Largest regional market: North America, holding a 44.1% revenue share in 2025
• Fastest-growing regional market: Asia Pacific, through 2033

Behind these numbers lies a broader transformation: the healthcare industry is learning to turn scattered, messy, real-world data into structured, decision-grade evidence.

What's Driving the Real World Evidence Solutions Market

1. Growing Regulatory Support and Policy Frameworks

Regulators are no longer treating real-world evidence as a supplementary nice-to-have — they're actively building it into approval and safety pathways. In December 2025, the U.S. FDA removed a longstanding requirement that RWE submitted in drug and device applications include identifiable individual patient data, opening the door for de-identified registries, claims, and EHR networks to be used in regulatory reviews. Around the same time, the UK's MHRA launched a pilot RWE Scientific Dialogue Programme under its 2024–27 Data Strategy, offering companies confidential guidance on evidence-generation strategy.

These moves matter because regulatory uncertainty has historically been one of the biggest barriers to RWE adoption. As agencies like the FDA, EMA, MHRA, and PMDA establish clearer standards for data quality and study design, pharmaceutical and biotech companies gain the confidence to invest further in RWE infrastructure.

2. Rising Demand for Drug Safety and Post-Market Surveillance

As therapies grow more complex and regulatory scrutiny intensifies, the need to monitor drugs after they reach the market has never been greater. Adverse drug events are estimated to be the third leading cause of death in the U.S., contributing to between 250,000 and 300,000 deaths annually, according to the American Society of Pharmacovigilance. This sobering reality is pushing pharmaceutical companies and health systems toward RWE platforms capable of continuous safety monitoring and early detection of rare or long-term adverse effects.

3. Explosive Growth in Real-World Data Volume

Health-related data is expanding at a compound annual rate of roughly 36%, flowing in from electronic health records, insurance claims, disease registries, wearables, and patient-reported outcomes. Advances in data integration and interoperability are letting RWE platforms convert this flood of raw information into insights that pharmaceutical companies, payers, and providers can actually act on.

4. AI-Powered Analytics Unlocking New Value

Artificial intelligence is reshaping what's possible with real-world data. Vendors such as Saama, SAS Institute, Veradigm, and IQVIA are embedding AI and machine learning into their platforms to automate data curation, predictive modeling, and patient stratification. This is helping overcome one of the industry's toughest challenges: harmonizing fragmented, inconsistent datasets into unified, analysis-ready evidence — accelerating everything from drug development to value-based care initiatives.

Ready to Explore the Full Market Opportunity? Download a Free Sample Report — Get detailed market data, segment-level forecasts, and competitive insights on the Real World Evidence Solutions Market straight from Grand View Research's proprietary databases.

Where RWE Solutions Are Being Applied

Real-world evidence isn't a single-use tool — it's woven into multiple stages of the healthcare and life sciences value chain:

• Drug Development & Approvals — the largest application segment, holding a 28.7% revenue share in 2025. RWE helps pharmaceutical companies and regulators streamline development timelines and support approval decisions, including for medical devices, where the FDA has issued specific guidance on using RWD in clearance decisions.
• Reimbursement/Coverage and Regulatory Decision-Making — the fastest-growing application, as countries increasingly formalize RWE use across a product's full lifecycle, from pre-marketing activities to post-marketing label changes.
• Post-Market Safety & Adverse Events Monitoring — critical given the scale of ADR-related harm, this application supports ongoing pharmacovigilance efforts.
• Medical Device Development & Approvals — a growing use case as device makers integrate decades of clinical and real-world data into next-generation product design.

Key Industry Segments

By Component: The services segment dominates, accounting for 58.1% of revenue in 2025, reflecting strong demand from pharmaceutical, biotech, and provider organizations for expert-led RWE support. The data sets segment — spanning clinical settings data, claims data, pharmacy data, and patient-powered data — is set to grow significantly as organizations lean further into outcomes-based, evidence-driven research.

By Therapeutic Area: Oncology leads with a 23.1% share in 2025, driven by RWE's proven ability to lower clinical trial costs and speed regulatory approval in a field facing roughly 10 million new cancer cases and 9.7 million cancer-related deaths globally each year (GLOBOCAN, 2022). Cardiology is poised for strong growth, with roughly 64% of U.S. cardiologists expressing strong interest in RWE-focused educational programs, according to the American College of Cardiology Foundation.

By End Use: Healthcare companies — pharmaceutical, biopharmaceutical, and medical device firms — hold the largest revenue share, driven by the need to avoid costly drug recalls and validate real-world performance. Healthcare payers are expected to grow fastest, as RWE increasingly informs reimbursement decisions; notably, RWE has already been cited in nearly 16% of clinical findings payers use for specialty drug decisions.

By Region: North America leads with a 44.1% share, underpinned by strong regulatory backing and R&D investment, while Asia Pacific is forecast to grow fastest, propelled by government digitization initiatives and a rising base of contract research organizations in China and India.

The Road Ahead

With regulators actively lowering adoption barriers, data volumes climbing at scale, and AI transforming raw information into usable insight, the real world evidence solutions market is positioned for sustained, meaningful growth through 2033. Recent moves — from Thermo Fisher's January 2026 launch of the CoreVitas Obesity Registry to Datavant and AWS's cloud-based real-world data platform — signal an industry racing to make evidence generation faster, more secure, and more collaborative.

For pharmaceutical companies, payers, and healthcare providers alike, the message is clear: real-world evidence is no longer optional infrastructure. It's becoming the backbone of how healthcare decisions get made.

Speak to Our Research Analysts — Need a customized view of this market? Connect with our team to tailor the report to your region, segment, or strategic focus.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Explore our dedicated business services:

• U.S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.